Personalized medicine into the next generation

Journal of Internal Medicine

Volumn 277, Issue 2, 2015, Pages 152-154

  Ingelman Sundberg, M ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Biomarkers; Drug metabolism; Pharmacogenomic labels; Pharmacogenomics; Polymorphism

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; NEUROLEPTIC AGENT; PROTEIN ANTIBODY; SODIUM CHANNEL NAV1.1; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CFTR PROTEIN, HUMAN; CYP2C19 PROTEIN, HUMAN;

ARTICLE; CANCER THERAPY; CYSTIC FIBROSIS; DEPRESSION; DNA POLYMORPHISM; GENETIC VARIABILITY; HLA SYSTEM; HUMAN; HUMAN GENOME; KIDNEY CANCER; LUNG CANCER; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PRIORITY JOURNAL; PSYCHIATRY; RHEUMATOID ARTHRITIS; BLOOD; DEPRESSIVE DISORDER; DIABETES MELLITUS, TYPE 2; GENETICS; KIDNEY NEOPLASMS; LUNG NEOPLASMS; ONCOLOGY;

ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; CYTOCHROME P-450 CYP2C19; CYTOCHROME P-450 CYP2D6; DEPRESSIVE DISORDER; DIABETES MELLITUS, TYPE 2; HUMANS; INDIVIDUALIZED MEDICINE; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MEDICAL ONCOLOGY;

EID: 84921519978     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12325     Document Type: Article

References (13)

1. Sim SC, Ingelman-Sundberg M. Pharmacogenomic biomarkers: new tools in current and future drug therapy. Trends Pharmacol Sci 2011; 32: 72-81.
2. Meyer UA, Zanger UM, Schwab M. Omics and drug response. Annu Rev Pharmacol Toxicol 2013; 53: 475-502.
3. Ivanov M, Barragan I, Ingelman-Sundberg M. Epigenetic mechanisms of importance for drug treatment. Trends Pharmacol Sci 2014; 35: 384-96.
4. Ehmann F, Caneva C, Prasad K et al. Pharmacogenomic Information in Drug Labels - European Medicines Agency perspective. Pharmacogenomics J 2015.
5. Maliepaard M, Nofziger C, Papaluca M et al. Pharmacogenetics in the evaluation of new drugs: a multiregional regulatory perspective. Nat Rev Drug Discov 2013; 12: 103-15.
6. Stingl J, Viviani R. Pharmacogenetics of CYP2D6 and CYP2C19 and individual response in psychiatry. J Intern Med 2015; 277: 167-77.
7. Walker LE, Mirza N, Yip VL et al. Personalized medicine approaches in epilepsy. J Intern Med 2015; 277: 218-34.
8. Rodríguez-Antona C, Taron M. Personalized medicine in oncology. J Intern Med 2015; 277: 201-17.
9. Huizinga TW. Personalized medicine in rheumatoid arthritis: is the glass half full or empty? J Intern Med 2015; 277: 178-87.
10. Amaral MD. Novel personalized therapy for Cystic fibrosis: treating the basic defect in 100% of CF patients. J Intern Med 2015; 277: 155-66.
11. Zawacka-Pankau J, Selivanova G. Pharmacological reactivation of p53 as a strategy to combat cancer. J Intern Med 2015; 277: 248-59.
12. Emami-Riedmaier A, Schaeffler E, Nies AT et al. Stratified medicine for the use of anti-diabetic medication in treatment of T2DM and cancer: where do we go from here? J Intern Med 2015; 277: 235-47.
13. Milani L, Leitsalu L, Metspalu A. Personalized medicine in an epidemiological perspective: estonian experience. J Intern Med 2015; 277: 188-200.